Beijing Konruns Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 603590.SS

Beijing Konruns Pharmaceutical Co.,Ltd. Free Cash Flow Yield on January 27, 2025: 2.63%

Beijing Konruns Pharmaceutical Co.,Ltd. Free Cash Flow Yield is 2.63% on January 27, 2025, a 25.23% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Beijing Konruns Pharmaceutical Co.,Ltd. 52-week high Free Cash Flow Yield is 3.03% on September 23, 2024, which is 15.50% above the current Free Cash Flow Yield.
Beijing Konruns Pharmaceutical Co.,Ltd. 52-week low Free Cash Flow Yield is 1.97% on February 28, 2024, which is -24.87% below the current Free Cash Flow Yield.
Beijing Konruns Pharmaceutical Co.,Ltd. average Free Cash Flow Yield for the last 52 weeks is 2.48%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603590.SS

Beijing Konruns Pharmaceutical Co.,Ltd.

CEO	Ms. Yuping Sun
IPO Date	Sept. 3, 2018
Location	China
Headquarters	Building 3
Employees	447
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research, production, and sale of various drugs in China. The company offers Su Ling product in the hemagglutinin preparation market used to reduce bleeding during surgery and control postoperative surgery. It also engages in the development of drug candidates, including CX1026, CX1003, and KC1036. The company was founded in 2003 and is headquartered in Beijing, China.

Key trends

Past 5 years